2017 Generic Drug Access & Savings in the U.S.
Photo Credit: Source: AAM Member Survey, 2017.

2017 Generic Drug Access and Savings in the U.S. Report

View the 2018 Generic Drug Access & Savings in the U.S. report.

Nearly 3.9 Billion Generic Prescriptions Were Dispensed in 2016

The ninth annual Generic Drug Access and Savings in the U.S. report demonstrates the vital role that generics and biosimilars play in the United States’ healthcare system. For the first time, the third-party researchers who conducted the study analyzed the differences between brand and generic abandonment behaviors and found some surprising results.

AAM-Access-Savings-Report-2017-cover

Download Report


The Context

Congress, the Trump Administration, and many state governments have been considering a range of policy options to address the costs of prescription drugs. AAM promotes policies to accelerate development of and access to more generics and biosimilars while blocking policies that would result in reduced access. The report documents massive improvements in quality of life and health outcomes for patients, federal and state taxpayers, employers, providers, and others. Monetary savings are a significant part of the story, but access entails a range of other benefits.

Savings Generated from Generic Drugs Continue to Soar

Generic drugs have saved the U.S. health care system $1.67 trillion in the last decade, generating $253 billion in savings in 2016 alone. Medicare savings amounted to $77 billion ($1,883 per enrollee) and Medicaid savings of $37.9 billion ($512 per enrollee). Generics account for 89% of prescriptions dispensed but only 26% of total drug costs in the US.

The report also looks at state-by-state savings and generic savings by therapy area. Notably, the most savings from generic drugs were found in mental health ($44 billion), hypertension ($29 billion) and cholesterol ($28 billion) treatments.

Generic Savings - Over Past 10 Years

Generic Drug Access & Savings Report - Medicare and Medicaid

Generics Savings By Therapy Type

Twitter Icon
#genericdrugs lower #healthcare costs: US has saved $1.67 trillion since 2007: http://bit.ly/RxAccessReport

 

Twitter Icon
Generic drugs saved #Medicare $77 billion and #Medicaid $37.9 in 2016. Find out more at http://bit.ly/RxAccessReport

 

Twitter Icon
#Generic savings by therapy area - putting treatments within reach and saving Americans $253 billion http://bit.ly/RxAccessReport

 

Nearly 3x as Many Patients Abandon Branded Prescriptions as Generics

For the first time, the third-party researchers who conducted the study analyzed the differences between brand and generic “abandonment” behaviors. That is, once patients request a prescription at the pharmacy, do they pick it up, or do they abandon a medication that could improve their lives? The report concludes that new patient abandonment rates for brand-name drugs are 266% higher than for generic drugs. Copays play a significant role in abandonment; 90 percent of generic copays are under $20, compared to 39 percent of branded copays.

Brand Drug Costs vs. Generic Savings Generics Savings Compare to Brand Drugs Generic Savings - Total Healthcare Spending

Twitter Icon
#genericdrugs lower #healthcare costs: US has saved $1.67 trillion since 2007: http://bit.ly/RxAccessReport

 

Twitter Icon
New analysis shows abandonment rate for brand-name prescriptions is 266% higher than for generic: http://bit.ly/RxAccessReport

Twitter Icon
#GenericDrugs save us all money by keeping #Rx costs competitive. See how much your state saved in a new @AccessibleMedicines report: http://bit.ly/RxAccessReport

We encourage you to mention, share and retweet @AccessibleMeds with shareable images and advocate for lower #drugprices.

Download Digital Media Toolkit
 

Savings By State

Generic drugs save us all money by keeping prescription costs competitive. Explore the map below to see how much your state saved in 2016.

Explore Interactive Map

Generic Savings by State - Map 2017

 

Erica Klinger


By Erica Klinger, AAM Marketing Director

 

 

 

Learn how your generic and biosimilar industry is committed to your health.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.